Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call GlobeNewswire - Thu May 7, 7:00AM CDT

MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

CELC : 131.06 (+0.27%)
Satellite view of the Middle East and the Strait of Hormuz with Iran highlighted_ Image by FoxPictures via Shutterstock_
Stocks Fall Amid Rising Middle East Tensions Barchart - Mon May 4, 3:39PM CDT

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.41%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. June E-mini...

MSTR : 187.59 (+4.31%)
SNDK : 1,562.34 (+16.60%)
GLXY : 30.23 (+3.17%)
COIN : 201.16 (+4.25%)
STX : 782.64 (+2.11%)
WDC : 480.00 (+3.47%)
UPS : 100.78 (+0.68%)
^BTCUSD : 80,860.24 (+0.92%)
SPY : 737.62 (+0.83%)
GME : 24.28 (+1.29%)
ADSK : 244.50 (-2.61%)
MU : 746.81 (+15.49%)
Loooking up a tall building in NYC by Andres Garcia via Unsplash
Stocks Mixed on Middle East Tensions and Solid Corporate Earnings Barchart - Mon May 4, 9:14AM CDT

The S&P 500 Index ($SPX ) (SPY ) today is down -0.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.19%. June E-mini S&P futures (ESM26...

MSTR : 187.59 (+4.31%)
AMAT : 435.44 (+6.04%)
SNDK : 1,562.34 (+16.60%)
INTU : 396.31 (-2.57%)
CELC : 131.06 (+0.27%)
GLXY : 30.23 (+3.17%)
EXPD : 156.69 (+3.18%)
$IUXX : 29,234.99 (+2.35%)
COIN : 201.16 (+4.25%)
ZNM26 : 110-185 (-0.16%)
MSFT : 415.12 (-1.34%)
PRU : 100.81 (+1.38%)
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort GlobeNewswire - Fri May 1, 4:03PM CDT

MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline...

CELC : 131.06 (+0.27%)
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed Mar 25, 3:01PM CDT

The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July...

CELC : 131.06 (+0.27%)
Celcuity Faces Widening Losses as Analysts Await Critical Earnings Report Barchart - Tue Mar 24, 4:04PM CDT

CELC : 131.06 (+0.27%)
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call GlobeNewswire - Wed Mar 18, 7:00AM CDT

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

CELC : 131.06 (+0.27%)
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology GlobeNewswire - Mon Mar 9, 4:42PM CDT

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus...

CELC : 131.06 (+0.27%)
Celcuity To Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 3:01PM CST

MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian...

CELC : 131.06 (+0.27%)
Celcuity Appoints Charles Romp to its Board of Directors GlobeNewswire - Thu Feb 12, 3:05PM CST

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment...

CELC : 131.06 (+0.27%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply Barchart - Sun May 10, 4:00PM CDT
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.